• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

N端聚乙二醇化对用于胰腺导管腺癌(PDAC)的基于肽的癌症表位合成及纯化的影响

Impact of N-Terminal PEGylation on Synthesis and Purification of Peptide-Based Cancer Epitopes for Pancreatic Ductal Adenocarcinoma (PDAC).

作者信息

Luna Omar F, Perez Yomkippur V, Ferrari Daniele P, Sayedipour Sana S, Royo Miriam, Acosta Gerardo A, Cruz Luis J, Alves Frauke, Agner Erik, Sydnes Magne O, Albericio Fernando

机构信息

Department of Organic Chemistry, University of Barcelona, and CIBER-BBN, Networking Centre on Bioengineering, Biomaterials, and Nanomedicine, Barcelona 08028, Spain.

Polypure AS, Martin Linges vei 25, Fornebu 1364, Norway.

出版信息

ACS Omega. 2024 Aug 1;9(32):34544-34554. doi: 10.1021/acsomega.4c02604. eCollection 2024 Aug 13.

DOI:10.1021/acsomega.4c02604
PMID:39157077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11325526/
Abstract

Peptide-based cancer vaccines have shown promising results in preclinical trials focusing on tumor immunotherapy. However, the presence of hydrophobic amino acid segments within these peptide sequences poses challenges in their synthesis, purification, and solubility, thereby hindering their potential use as cancer vaccines. In this study, we successfully synthesized peptide sequences derived from mesothelin (MSLN), a tumor-associated antigen overexpressed in pancreatic ductal adenocarcinoma (PDAC) by conjugating them with monodisperse polyethylene glycol (PEG). By PEGylating mesothelin epitopes of varying lengths (ranging from 9 to 38 amino acids) and hydrophobicity (60-90%), we achieved an effective method to improve the peptide yield and facilitate the processes of synthesis and purification. PEGylation significantly enhanced the solubility, facilitating the single-step purification of lengthy hydrophobic peptides. Most importantly, PEGylation did not compromise cell viability and had little to no effect on the immunogenicity of the peptides. In contrast, the addition of a palmitoyl group to increase immunogenicity led to reduced yield and solubility. Overall, PEGylation proves to be an effective technique for enhancing the solubility and broadening the range of utility of diverse long hydrophobic peptides.

摘要

基于肽的癌症疫苗在专注于肿瘤免疫疗法的临床前试验中已显示出有前景的结果。然而,这些肽序列中存在疏水性氨基酸片段,在其合成、纯化和溶解性方面带来了挑战,从而阻碍了它们作为癌症疫苗的潜在应用。在本研究中,我们通过将源自间皮素(MSLN)的肽序列与单分散聚乙二醇(PEG)偶联,成功合成了该肽序列,间皮素是一种在胰腺导管腺癌(PDAC)中过表达的肿瘤相关抗原。通过对不同长度(9至38个氨基酸)和疏水性(60 - 90%)的间皮素表位进行聚乙二醇化,我们实现了一种有效方法来提高肽产量并促进合成和纯化过程。聚乙二醇化显著增强了溶解性,便于对长链疏水肽进行单步纯化。最重要的是,聚乙二醇化不会损害细胞活力,并且对肽的免疫原性几乎没有影响。相比之下,添加棕榈酰基以增加免疫原性会导致产量和溶解性降低。总体而言,聚乙二醇化被证明是一种有效技术,可增强溶解性并拓宽各种长链疏水肽的应用范围。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/78637f7e7a1e/ao4c02604_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/239b03b95038/ao4c02604_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/0b1fb278d8c9/ao4c02604_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/e97300a5b895/ao4c02604_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/a4445df3456f/ao4c02604_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/78637f7e7a1e/ao4c02604_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/239b03b95038/ao4c02604_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/0b1fb278d8c9/ao4c02604_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/e97300a5b895/ao4c02604_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/a4445df3456f/ao4c02604_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/11325526/78637f7e7a1e/ao4c02604_0005.jpg

相似文献

1
Impact of N-Terminal PEGylation on Synthesis and Purification of Peptide-Based Cancer Epitopes for Pancreatic Ductal Adenocarcinoma (PDAC).N端聚乙二醇化对用于胰腺导管腺癌(PDAC)的基于肽的癌症表位合成及纯化的影响
ACS Omega. 2024 Aug 1;9(32):34544-34554. doi: 10.1021/acsomega.4c02604. eCollection 2024 Aug 13.
2
Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).胰腺导管腺癌(PDAC)中 Mesothelin 的过表达。
Int J Med Sci. 2020 Feb 4;17(4):422-427. doi: 10.7150/ijms.39012. eCollection 2020.
3
Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment.胰腺癌患者血清间皮素水平低是由于脱落的间皮素在肿瘤微环境中潴留所致。
Transl Oncol. 2022 Jul;21:101440. doi: 10.1016/j.tranon.2022.101440. Epub 2022 May 4.
4
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.从恶性进展到治疗靶点:胰腺导管腺癌中间皮素的最新研究进展。
Int J Mol Sci. 2020 Jun 6;21(11):4067. doi: 10.3390/ijms21114067.
5
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.分泌抗-FAP/抗-CD3 分子的间皮素 CAR T 细胞可有效靶向胰腺腺癌及其基质。
Clin Cancer Res. 2024 May 1;30(9):1859-1877. doi: 10.1158/1078-0432.CCR-23-3841.
6
Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.自组装吉西他滨前药纳米粒对患者来源的胰腺导管腺癌显示出增强的疗效。
ACS Appl Mater Interfaces. 2020 Jan 22;12(3):3327-3340. doi: 10.1021/acsami.9b16209. Epub 2020 Jan 7.
7
Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.解析唾液酸对胰腺癌免疫图谱和免疫治疗效果的影响。
J Immunother Cancer. 2023 Nov;11(11). doi: 10.1136/jitc-2023-007805.
8
Effect of PEGylation on Host Defense Peptide Complexation with Bacterial Lipopolysaccharide.聚乙二醇化对宿主防御肽与细菌脂多糖复合物形成的影响。
Bioconjug Chem. 2021 Aug 18;32(8):1729-1741. doi: 10.1021/acs.bioconjchem.1c00259. Epub 2021 Jul 20.
9
Pegylated peptides. II. Solid-phase synthesis of amino-, carboxy- and side-chain pegylated peptides.聚乙二醇化肽。II. 氨基、羧基和侧链聚乙二醇化肽的固相合成
Int J Pept Protein Res. 1994 Feb;43(2):127-38.
10
A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.一种新型靶向 GPC1 的补体固定 IgM 抗体作为治疗胰腺导管腺癌的有效免疫治疗策略。
J Transl Med. 2023 Nov 28;21(1):864. doi: 10.1186/s12967-023-04745-9.

引用本文的文献

1
Anti-Tumor Efficacy of a Mesothelin-Based Nanovaccine in a KPC Orthotopic Mouse Model of Pancreatic Cancer.基于间皮素的纳米疫苗在胰腺癌KPC原位小鼠模型中的抗肿瘤疗效
Vaccines (Basel). 2025 Mar 14;13(3):314. doi: 10.3390/vaccines13030314.

本文引用的文献

1
Poly(I:C) and R848 ligands show better adjuvanticity to induce B and T cell responses against the antigen(s).聚肌胞苷酸(Poly(I:C))和R848配体在诱导针对抗原的B细胞和T细胞应答方面表现出更好的佐剂性。
Heliyon. 2024 Feb 27;10(5):e26887. doi: 10.1016/j.heliyon.2024.e26887. eCollection 2024 Mar 15.
2
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.胰腺癌:发病机制、筛查、诊断和治疗。
Gastroenterology. 2022 Aug;163(2):386-402.e1. doi: 10.1053/j.gastro.2022.03.056. Epub 2022 Apr 7.
3
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
4
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens.用 R848 和 poly(I:C) 激活的血液树突状细胞可诱导针对病毒和肿瘤相关抗原的特异性免疫反应。
Cancer Immunol Immunother. 2022 Jul;71(7):1705-1718. doi: 10.1007/s00262-021-03109-w. Epub 2021 Nov 25.
5
Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.超越单纯的肽抗原:基于肽的癌症疫苗的复杂世界。
Front Immunol. 2021 Jun 30;12:696791. doi: 10.3389/fimmu.2021.696791. eCollection 2021.
6
Palmitoylated antigens for the induction of anti-tumor CD8 T cells and enhanced tumor recognition.用于诱导抗肿瘤CD8 T细胞和增强肿瘤识别的棕榈酰化抗原。
Mol Ther Oncolytics. 2021 Apr 29;21:315-328. doi: 10.1016/j.omto.2021.04.009. eCollection 2021 Jun 25.
7
Advances in the management of pancreatic ductal adenocarcinoma.胰腺导管腺癌管理方面的进展
CMAJ. 2021 Jun 7;193(23):E844-E851. doi: 10.1503/cmaj.201450.
8
Therapeutic cancer vaccines.治疗性癌症疫苗。
Nat Rev Cancer. 2021 Jun;21(6):360-378. doi: 10.1038/s41568-021-00346-0. Epub 2021 Apr 27.
9
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.一项化疗联合或不联合 Algenpantucel-L(HyperAcute-Pancreas)免疫疗法治疗局部晚期不可切除或边缘可切除胰腺癌的 3 期随机临床试验。
Ann Surg. 2022 Jan 1;275(1):45-53. doi: 10.1097/SLA.0000000000004669.
10
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).PEG 化重组人粒细胞集落刺激因子在吉西他滨治疗失败后的转移性胰腺癌二线治疗随机 III 期研究(SEQUOIA)
J Clin Oncol. 2021 Apr 1;39(10):1108-1118. doi: 10.1200/JCO.20.02232. Epub 2021 Feb 8.